{
    "organizations": [],
    "uuid": "b0041edc00d5ef143ac3fe4864170a2743dfedd3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-forty-seven-says-agreement-with-me/brief-forty-seven-says-agreement-with-merck-kgaa-to-conduct-clinical-trials-for-patients-with-ovarian-cancer-idUSFWN1P60KN",
    "ord_in_thread": 0,
    "title": "BRIEF-Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 40 PM / in 6 minutes BRIEF-Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer Reuters Staff 1 Min Read \nJan 11 (Reuters) - Merck KGAA: \n* FORTY SEVEN - AGREEMENT WITH MERCK KGAA TO CONDUCT PHASE 1B CLINICAL TRIAL COMBINING HU5F9-G4 WITH AVELUMAB IN PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage:",
    "published": "2018-01-11T14:40:00.000+02:00",
    "crawled": "2018-01-11T14:53:10.060+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "seven",
        "say",
        "agreement",
        "merck",
        "kgaa",
        "conduct",
        "clinical",
        "trial",
        "patient",
        "ovarian",
        "cancer",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "merck",
        "kgaa",
        "forty",
        "seven",
        "agreement",
        "merck",
        "kgaa",
        "conduct",
        "phase",
        "1b",
        "clinical",
        "trial",
        "combining",
        "avelumab",
        "patient",
        "ovarian",
        "cancer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}